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Abstract
Background: New treatment strategies are emerging to target DNA damage response pathways in ovarian cancer.
Our group has previously shown that the class I biased HDAC inhibitor romidepsin (FK228) induces DNA damage
response and has potent cytotoxic effects in ovarian cancer cells. Here, we investigated newly discovered HDAC
inhibitors, thailandepsin A (TDP-A) and thailandepsin B (TDP-B), to determine the effects on cell viability, apoptosis
and DNA damage response in ovarian cancer cells.
Methods: FK228, TDP-A and TDP-B were tested in five ovarian cancer cell lines. Cellular viability was measured by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Immunofluorescence assays were used to
assess activated caspase 3. Western blots were performed to detect protein expression of PARP cleavage, pH2AX,
P-glycoprotein and tubulin acetylation.
Results: Treatment with TDPs decreased cell viability at nanonomolar concentrations in four of the five ovarian
cancer cell lines studied. Similar to FK228, both TDP compounds exerted minimal effects on NCI/ADR-RES ovarian
cancer cells. Across the four cell lines sensitive to the TDPs, TDP-B consistently had a greater inhibitory effect than
TDP-A on cell viability. TDP-B also had relatively greater effects on promoting cell apoptosis and induction of
pH2AX (a mark of DNA damage response), than TDP-A. These antitumor effects of TDP-B were of similar
magnitude to those induced by an equal concentration of FK228. Similar to FK228, the nanomolar concentrations
of the TDPs had little effect on tubulin acetylation (a mark of class II HDAC6 inhibition).
Conclusions: The new small molecule HDAC inhibitors TDP-A and TDP-B are FK228 analogues that suppress cell
viability and induce apoptosis at nanomolar drug concentrations. TDP-B showed the most similarity to the
biological activity of FK228 with greater cytotoxic effects than TDP-A in vitro. Our results indicate that FK228-like
small molecule class I HDAC-biased HDAC inhibitors have therapeutic potential for ovarian cancer.
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Background
Ovarian cancer is the deadliest gynecologic cancer in the
United States [1]. Despite aggressive treatment strategies
that involve extensive surgical tumor debulking followed
by combination platinum-based chemotherapy, the
overall prognosis of ovarian cancer remains poor. More
than 50% of high-grade ovarian cancers contain
abnormalities in DNA damage repair pathways [2] and
are theoretically more sensitive to DNA damaging che-
motherapy drugs. Our group has an ongoing interest in
an approach of targeting histone deacetylases (HDACs),
which are chromatin modifying enzymes known to be
associated with DNA damage and repair [3-7].
Based on a screen of a panel of small molecule HDAC
inhibitors, we have shown that the depsipeptide
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romidepsin (FK228) to be the most potent in the major-
ity of ovarian cancer cell lines examined [8]. FK228
induced cytotoxic effects measured by induction of a
DNA damage response mark, inhibition of cell prolifera-
tion and increased cell death. FK228 was isolated from
Chromobacterium violaceum no. 968, a rare Gram nega-
tive bacterium, and recently approved for the treatment
of cutaneous and peripheral T-cell lymphomas [9,10].
The primary mechanism of action of FK228 requires
reduction of a characteristic disulfide bond that creates
a “warhead” thiol group. The thiol binds to zinc in the
catalytic center of both class I and class II HDACs and
inhibits HDAC enzymatic activity [11]. However, FK228
binding activity to class I HDACs is considerably more
potent than to class II HDACs [11].
Thailandepsin A (TDP-A) and thailandepsin B (TDP-
B) are newly reported potent HDAC inhibitors discov-
ered from Burkholderia thailandensis E264 by means of
genome mining by the Cheng group [12]. Similar to
FK228 [11], the TDPs share a conserved bicyclic depsi-
peptide structure, and require a reduced state for the
most potent HDAC binding activity [12]. The goal of
this study was to determine the anti-tumor effects of
these newly discovered “FK228-like” TDPs in ovarian
cancer cell lines. We hypothesized that the unique che-
mical structure of FK228 and compounds with similar
properties such as TDPs leads to strong binding in
enzymatic assays to class I HDACs and contributes to
potent antitumor activity. Here, we show that TDP-B
has greater cytotoxic effects than TDP-A in ovarian can-




Romidepsin (FK228) was obtained from Gloucester
Pharmaceuticals, Celgene Corporation, Cambridge, MA.
The TDPs, TDP-A and TDP-B, were discovered,
patented, and provided by the Cheng group [12].
Dimethyl sulfoxide (DMSO) (Sigma Chemical Co., St
Louis, MO), at a concentration of 0.01%, was used as a
vehicle.
Cell culture
The epithelial ovarian cancer cell lines SKOV-3,
OVCAR-8 and NCI/ADR-RES were grown in RPMI
1640 medium supplemented with 10% fetal bovine
serum and penicillin/streptomycin, and passaged using
standard methods [8,13]. SKOV-3 (American Type Cul-
ture Collection, Manassas, VA), OVCAR-8, and NCI/
ADR-RES cells (National Cancer Institute, Bethesda,
MD) are well-characterized as part of the National Can-
cer Institute 60 Cancer Panel [14,15]. UWB1.289 (Brca1
null) and UWB1.289 + BRCA1 (Brca1 wild type) cell
lines (American Type Culture Collection) were main-
tained as previously described [16]. All cell lines were
used within 6 months of receipt and tested negative for
mycoplasma prior to the following experiments.
Cell viability assays
Cell viability assays using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (Sigma) were
conducted using established methods [8]. SKOV3 and
OVCAR8 cells were seeded at a density of 1250 cells/
well in 384 well plates (Corning Life Sciences, Lowell,
MA), while NCI/ADR-RES cells were seeded at 1750
cells/well. Absorbance was measured at 540 nm using a
Spectramax M5 spectrophotometer (Molecular Devices,
Sunnyvale, CA). Cell viability was determined by mea-
suring the percentage of viable treated cells compared
to controls.
Immunofluorescence
SKOV-3 ovarian cancer cells were fixed, permeabilized
and stained with anti-caspase 3 (Cell Signaling Technol-
ogy, Inc, Danvers, MA) as per established protocols
[8,17]. Binding of the primary antibody was detected
with Alexa Flour anti-mouse IgG 488 secondary antibo-
dies (Invitrogen, Carlsbad, CA), as appropriate. Nuclei
were counterstained with DAPI (Millipore Corp., Biller-
ica, MA). Fluorescence microscopy images were cap-
tured in 24-bit TIFF format with a Zeiss Axiocam HRC
camera (Carl Zeiss MicroImaging Inc.) using Zeiss Axio-
vision 3.1 software, and analyzed as previously described
[8,17].
Western blot analysis
Whole cell protein isolation, Western Blotting and sig-
nal detection were performed as described from NCI/
ADR-RES, OVCAR-8 and SKOV-3 ovarian cancer cells
[13,18]. For histone extraction, cell pellets were resus-
pended in an extraction buffer: PBS containing 0.5%
Triton X100 (v/v) (Sigma), 2 mM phenylmethylsulfonyl
fluoride (Sigma) and 1:100 dilutions of protease and
phosphatase inhibitor cocktails (Sigma). Cells were lysed
on ice for 10 min and centrifuged for 10 min at 2000
rpm at 4°C. The pellet was resuspended in 0.2 N hydro-
chloric acid (Sigma) supplemented with protease and
phosphatase inhibitors and acid extracted overnight at
4°C. The samples were centrifuged for 10 min at 2000
rpm at 4°C, and the supernatant was collected for
further analysis.
The following antibodies were used: anti-phospho
H2AX (Ser139) and anti-histone H3, (Millipore); anti-P-
glycoprotein (PgP), anti-acetylated a-tubulin, anti-a-
tubulin and anti-b-Actin (Sigma); and anti-Poly (ADP-
ribose) polymerase (PARP) (Cell Signaling, Beverly,
MA). Where applicable, corresponding levels of b-Actin,
Wilson et al. Journal of Ovarian Research 2012, 5:12
http://www.ovarianresearch.com/content/5/1/12
Page 2 of 7
a-tubulin or histone H3 were determined to ensure
equal protein loading.
Statistics
Unless otherwise indicated, values are the mean + SE of
at least three independent experiments with p < 0.05
relative to control using the Student’s t test.
Results
Newly discovered small molecule HDAC inhibitors TDP-A
and TDP-B are FK228 analogues
Our group’s experience with FK228 has led us to specu-
late that there are unique features of FK228 that contri-
bute to its potency in ovarian cancer cells. The strong
inhibitory activity against class I HDACs compared to
class II HDACs is well-known [11]. It is possible that
this preferential class I HDAC binding contributes to
the cytotoxic effects of FK228. The TDPs and FK228
share a conserved bicyclic depsipeptide structure that
differs significantly from SAHA, a hydroxamic acid (Fig-
ure 1). In this study we asked if TDPs, HDAC inhibitors
with similar chemical and class I HDAC binding proper-
ties, produce similar biological effects in ovarian cancer
cells.
TDP-A and TDP-B inhibit cell viability at nanomolar
concentrations
The antiproliferative and cytotoxic activities of TDPs
have been compared to FK228 in sulphorhodamine B
cell growth assays in the NCI60 panel of cancer cell
lines [12]. Of the seven ovarian cancer cell lines present
in the panel, SKOV-3 cells were the most sensitive,
NCI/ADR-RES cells were profoundly resistant and
OVCAR-8 cells exhibited an intermediate response.
Therefore, we chose this subset of the NCI60 panel for
further investigation of the cytotoxic effects of the
TDPs. In addition, we included the well-characterized
isogenic Brca1 null and wild type (WT) cell lines in our
study, because of the high incidence of BRCA1 dysfunc-
tion in ovarian cancer [16].
First, we performed MTT assays to independently test
the effects of FK228 compared to those of the TDPs on
ovarian cancer cell viability in vitro. As shown in Figure
2A, TDP-B displayed similar inhibitory effects on cell
viability as an equal concentration of FK228 (10 nM) in
the three NCI60 cell lines and the isogenic Brca1 wild-
type and null cell pair. Although TDP-A (10 nM)
induced significant inhibitory effects on cell viability in
all cell lines except NCI/ADR-RES, the magnitude of
inhibition was consistently less than that observed for
TDP-B (Figure 2A). The NCI/ADR-RES ovarian cancer
cells were relatively resistant to FK228 and both TDP
compounds. Interestingly, we have published that NCI/
ADR-RES cells are exquisitely sensitive to SAHA, which
is structurally different from the FK228-like compounds
Figure 1 Chemical structure of HDAC inhibitors. Thailandepsin A
(TDP-A), thailandepsin B (TDP-B) and FK228 are depsipeptides
characterized by a bicyclic structure containing a signature disulfide
bond; the prodrugs can be activated by cellular reduction, indicated
by a star sign (*). SAHA is a hydroxamic acid marked by a pound
sign (#)
Figure 2 TDP-A and TDP-B inhibit ovarian cancer cell survival
at nanomolar concentrations. A) Representative graphs of NCI/
ADR-RES, OVCAR-8, SKOV-3, BRCA1 wild type and null ovarian
cancer cells treated with FK228, TDP-A and TDP-B at a fixed
concentration of 10 nM. MTT assays were performed to assess cell
proliferation after 72 h of treatment. Each treatment was replicated
6 times. Values are mean + SE for 3 independent experiments. B)
Representative Western blot for P-glycoprotein expression in NCI/
ADR-RES, OVCAR-8 and SKOV-3 ovarian cancer cells after 24 h of
treatment with 10nM FK228, 10nM TDP-A and 10nM TDP-B. 0.1%
DMSO was the vehicle control. b-actin was used as a loading
control.
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[8]. NCI/ADR-RES cell lines highly express the multi-
drug resistant gene mdr1/ABCB1 that encodes for PgP
[15]. FK228 is known to induce PgP [19-21], suggesting
that further upregulation of PgP contributes to relative
resistance to FK228. Similar to FK228, the TDPs upre-
gulated PgP in NCI/ADR-RES cells (Figure 2B). This
activation of PgP may contribute to the NCI/ADR-RES
cellular resistance to the TDPs. In contrast, PgP was not
detectable in the relatively sensitive cell lines, SKOV-3
and OVCAR-8, either in treated or untreated cells.
Brca1 null cells, which harbor a truncating Brca1
mutation, are known to be more sensitive than their
wild-type counterparts to various agents that promote
DNA damage [16]. In the MTT assays, the Brca1 status
of the cells was similarly observed to determine sensitiv-
ity to the small molecule HDAC inhibitors, since FK228
and the TDPs exerted greater effects in the Brca1 null
cells.
TDP-B has a greater effect on the activation of caspase-3
and PARP (markers of apoptosis) than TDP-A
Although TDP-A has previously been shown to exhibit
the greatest growth inhibitory effects across cell lines,
the cytotoxic activity of TDP-A is lower than FK228 and
TDP-B in ovarian cancer cells [12]. One possible
mechanism for the observed differences in cytotoxicity
is differential induction of apoptosis. Therefore, we
examined the effects of TDP-A and TDP-B on apoptosis
using two independent assays. Caspase 3 activation mea-
sured by immunofluorescence staining for cleaved cas-
pase 3 was similarly induced by FK228 and TDP-B
compared to controls in SKOV-3 cells (Figure 3), while
fewer TDP-A-treated cells displayed activated caspase-3.
Western blot analysis of PARP cleavage was performed
to validate these findings. Similarly, cleaved PARP was
activated by FK228 and TDP-B to a greater extent than
by TDP-A (Figure 4A). As anticipated by the relative
resistance to FK228 and the TDPs, there was no evi-
dence of apoptosis induction by these HDAC inhibitors
in NCI/ADR-RES cells.
TDP-A and TDP-B have differential effects on the DNA
damage response mark pH2AX
We have demonstrated previously that pH2AX (a sensi-
tive histone mark of DNA damage) is a useful indicator
of HDAC cytotoxicity and a potential mechanism for
inducing apoptosis in ovarian cancer [8,22]. Prolonged
induction of pH2AX foci after genotoxic injury is asso-
ciated with irreparable DNA damage and apoptosis [22].
Therefore, we evaluated the activation of pH2AX 24 h
after exposure to FK228, TDP-A and TDP-B. In rela-
tively sensitive ovarian cancer cells OVCAR-8 and
SKOV-3, FK228 and TDP-B induced pronounced upre-
gulation of pH2AX expression compared to controls
(Figure 4B). However, in TDP-A treated cells, pH2AX
activation was not as robust. In the NCI/ADR-RES cells,
pH2AX was minimally activated, reflecting the relative
resistance to FK228-like drugs.
Figure 3 TDP-B activates cleaved caspase-3 by
immunofluorescence. Representative immunofluorescence staining
for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated
with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The
nuclei are stained with DAPI (blue)
Figure 4 Representative Western blots show TDP-A and TDP-B
upregulate cleaved PARP and pH2AX. Western blot analysis of A)
cleaved PARP and B) pH2AX after 24 h of treatment with 10 nM
FK228, TDP-A and TDP-B in NCI/ADR-RES, OVCAR-8 and SKOV-3
ovarian cancer cells. The loading controls in A) and B) were b-actin
and histone H3, respectively.
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The FK228 analogues TDP-A and TDP-B are class I biased
HDAC inhibitors
Inhibition of class I HDACs is known to contribute to
DNA damage and cytotoxicity in ovarian cancer cells
[7,8]. The cellular responses we observed in the studies
presented here support our hypothesis that FK228-like
compounds that target class I HDACs exhibit potent
antitumor activity. Enzymatic assays comparing TDP-A
and TDP-B to FK228 have shown that both TDPs bind
to class I HDACs with 30-100 times more potency than
to class II HDACs [12] (Figure 5A). Therefore, we tested
the effects of TDP-A and TDP-B on a target of class II
HDAC6 inhibition, tubulin acetylation [23]. We evalu-
ated tubulin acetylation by Western blot after treatment
with TDPs and FK228 at drug concentrations that
inhibited cell viability and induced markers of apoptosis
and DNA damage response (Figure 5B). However, we
found no significant change in acetylated tubulin com-
pared to DMSO treated controls. These results suggest
that HDAC6 inhibition is not critical for the antitumor
effects of TDP-A and TDP-B, and are in line with pre-
vious data showing that low levels of tubulin acetylation
do not correlate with the biological activity of HDAC
inhibitors in ovarian cancer cells [8].
Discussion
In this study, we have shown that the recently discov-
ered FK228 analogues TDP-A and TDP-B inhibit cell
viability and promote apoptosis in ovarian cancer cells.
Furthermore, both agents lead to persistent pH2AX acti-
vation, which is a mark of DNA damage-associated cell
death [22]. TDP-B is more similar to FK228 in reducing
cell proliferation and activating markers of apoptosis
and DNA damage, suggesting that TDP-B is more cyto-
toxic than TDP-A in our system.
Studies such as ours support the underlying hypoth-
esis that FK228 and its analogues have potent antitumor
activity due to robust class I HDAC inhibitory function.
Interestingly, both the oxidized and reduced forms of
TDP-B show potent inhibition of HDAC3/NCOR activ-
ity [12]. Previous studies suggest that the class I
HDAC3 plays an important role in regulating DNA
damage response and is a theoretical target for therapy
in cancer cells [7,8,13]. We have shown previously that
siRNA knockdown of HDAC3 in ovarian cancer cells
contributes to suppression of cell proliferation [13]. The
structure of HDAC3 and its unique binding to co-regu-
lator N-COR was characterized recently [24]. One
potential mechanism of action of the selectivity of
Figure 5 TDPs are class I biased HDAC inhibitors and do not upregulate acetylated tubulin. A) HDAC inhibition of HDACs 1, 2, 3 and 6
measured by HDAC enzymatic assays, in which the compounds are reduced in test tubes [12]. B) Western blot analysis of acetylated tubulin in
NCI/ADR-RES, OVCAR-8 and SKOV-3 ovarian cancer cells. Tubulin was the loading control.
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FK228-like compounds is a chemical structure that
allows robust binding to HDAC3 and disruption of the
HDAC3-NCOR complex. Investigation into 1) precisely
how this disruption occurs and 2) whether there is a
benefit to selective HDAC3 and other class I HDACs
inhibitors is ongoing.
The precise reasons for the differences in activity
between the TDPs in our system warrant further study.
A recent report of the independently discovered bur-
kholdac B, shown to be identical to TDP-A, had potent
picomolar growth inhibitory activity in MCF7 breast
cancer cells [25]. These in vitro results of burkholdac B
were not consistent with the results of TDP-A published
by the Cheng group [12]. Further study of TDP-A is
warranted to investigate other mechanisms of growth
inhibition such as differentiation and senescence. Future
efforts to determine if the observed antitumor effects of
TDP-B can be recapitulated in vivo will be critical for
further development of the TDP compounds.
The efficacy of HDAC inhibitors in cancer therapy is
dependent on a number of factors. These factors
include: 1) chemical properties of the HDAC inhibitor;
2) strength and selectivity of HDAC inhibition; and 3)
phenotypic and molecular features of the cells. Different
chemical properties of HDAC inhibitors affect drug
availability, pharmacokinetics and pharmacodynamics
[3-7]. Furthermore, HDAC inhibitors are known to be
more effective when combined with other chemothera-
peutic agents [3,4,8]. We have unpublished results show-
ing that FK228 enhances the effects of the DNA
damaging agent cisplatin in ovarian cancer cells. Our
results are in line with a recent report showing that
FK228 is synergistic with DNA damaging agents when
given simultaneously [26].
The effects of HDAC inhibitors are not limited to
HDAC inhibition. Although the mechanisms are not
fully understood, HDAC inhibitors acetylate non-histone
molecules that could be exploited for therapeutic pur-
poses. For example, FK228 induces p53 acetylation and
may promote degradation of mutant p53 and enhance
sensitivity to cytotoxic agents [27]. Since over 90% of
high grade serous ovarian cancers harbor p53 mutations
[2], FK228 and its analogues may be useful in treating
these tumors. Although tubulin acetylation may play a
role, we have not shown tubulin acetylation to correlate
with the anti-tumor effects of HDACi in this report or
in the majority of ovarian cancer cell lines we have
screened [8].
Finally, the biological responses to FK228 and other
HDAC inhibitors depend on cell type [8,13,28,29].
Malignant cells are more sensitive to HDAC inhibitors
than normal cells and hematologic malignancies are
more sensitive than solid tumors to single agent treat-
ment with HDAC inhibitors [8,13,28,29]. The NCI/
ADR-RES cells are derived from the OVCAR-8 cells
[14,15], and represent acquired drug resistance asso-
ciated with PgP. This cell line pair is a good representa-
tion of the clinical status of chemotherapy-resistant
ovarian cancers. Thus, determinants of cellular sensitiv-
ity and resistance (ex. BRCA mutational status or high
PgP expression) as demonstrated here are important
considerations prior to treatment.
Conclusion
The newly discovered class I HDAC inhibitors TDP-A
and TDP-B have antiproliferative and proapoptotic bio-
logical activity in ovarian cancer cells [12]. TDP-B
appears to induce similar cytotoxic effects in vitro as
FK228 that are stronger than the in vitro effects demon-
strated by TDP-A. The specific components of FK228
and its analogues, along with molecular features that
determine cellular vulnerabilities, are critical for the
rational development of this chemical class of HDAC
inhibitors for the treatment of ovarian cancers and
other solid tumors.
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